First extensive immune profiling of sarcomas shows some likely susceptible to immunotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study published May 2 in the journal Cancer suggests how both existing and emerging immunotherapy treatments could be successful for sarcomas. Two sarcoma subtypes — leiomyosarcoma and pleomorphic — showed biological characteristics suggesting they are susceptible to an existing immunotherapy approach known as checkpoint inhibitors. This treatment works by blocking a protein that keeps immune cells from attacking cancerous cells.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login